345 related articles for article (PubMed ID: 19515014)
21. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor.
Chen Y; Ferguson SS; Negishi M; Goldstein JA
J Pharmacol Exp Ther; 2004 Feb; 308(2):495-501. PubMed ID: 14600250
[TBL] [Abstract][Full Text] [Related]
22. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
23. Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.
Flanagan JU; McLaughlin LA; Paine MJ; Sutcliffe MJ; Roberts GC; Wolf CR
Biochem J; 2003 Mar; 370(Pt 3):921-6. PubMed ID: 12482324
[TBL] [Abstract][Full Text] [Related]
24. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
25. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
26. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
27. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
Dickmann LJ; Locuson CW; Jones JP; Rettie AE
Mol Pharmacol; 2004 Apr; 65(4):842-50. PubMed ID: 15044613
[TBL] [Abstract][Full Text] [Related]
28. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
29. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.
Kumar V; Wahlstrom JL; Rock DA; Warren CJ; Gorman LA; Tracy TS
Drug Metab Dispos; 2006 Dec; 34(12):1966-75. PubMed ID: 16963489
[TBL] [Abstract][Full Text] [Related]
30. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site.
Ferguson SS; LeCluyse EL; Negishi M; Goldstein JA
Mol Pharmacol; 2002 Sep; 62(3):737-46. PubMed ID: 12181452
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.
Yale SH; Glurich I
J Altern Complement Med; 2005 Jun; 11(3):433-9. PubMed ID: 15992226
[TBL] [Abstract][Full Text] [Related]
32. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
[TBL] [Abstract][Full Text] [Related]
33. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
Mosher CM; Hummel MA; Tracy TS; Rettie AE
Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes.
Wang Z; Sun W; Huang CK; Wang L; Xia MM; Cui X; Hu GX; Wang ZS
Drug Dev Ind Pharm; 2015 Apr; 41(4):613-6. PubMed ID: 24517573
[TBL] [Abstract][Full Text] [Related]
35. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.
Scheer N; Kapelyukh Y; Chatham L; Rode A; Buechel S; Wolf CR
Mol Pharmacol; 2012 Dec; 82(6):1022-9. PubMed ID: 22918969
[TBL] [Abstract][Full Text] [Related]
36. Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.
Flora DR; Tracy TS
Drug Metab Dispos; 2012 Apr; 40(4):836-42. PubMed ID: 22205778
[TBL] [Abstract][Full Text] [Related]
37. Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha.
Surapureddi S; Rana R; Reddy JK; Goldstein JA
Mol Pharmacol; 2008 Sep; 74(3):913-23. PubMed ID: 18552123
[TBL] [Abstract][Full Text] [Related]
38. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
39. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19.
Jung F; Griffin KJ; Song W; Richardson TH; Yang M; Johnson EF
Biochemistry; 1998 Nov; 37(46):16270-9. PubMed ID: 9819219
[TBL] [Abstract][Full Text] [Related]
40. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
